OTC Stock Review suggests that growth oriented investors and traders look at next-generation biomedical technology developer Biophan Technologies, Inc. (OTCBB:BIPH), this morning. Biophan just announced a definitive license agreement with NYSE-listed Boston Scientific covering multiple patents related to Magnetic Resonance Imaging (MRI) safety and image compatibility. Friday after the close, Biophan disclosed that Boston Scientifics' $5.75 million investment will be made by August 15, 2005 and their license will produce royalties of 3-5%, which can mean tens of millions in potential royalties. The big news is that Boston Scientifics' investment, the result of their recently announced licensing pact, will allow Biophan to file for a listing on a major stock exchange. Additionally, Biophan's 10-Q filing clarified their acquisition and development of technology to: improve vascular stents so they can be imaged with MRI; enable an MRI visible vena cava; enhance the MRI safety and MRI image compatibility of pacemakers; improve MRI contrast agents; improve drug elution and drug delivery systems; and develop a system for generating power for implantable devices from body heat, in cooperation with NASA.

A February 15, 2005 Business Week article referred to Biophan as one of seven nanotechnology players in the healthcare sector. Their technologies make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. Biophan and its licensors hold 142 U.S. patents, licenses, or applications in the areas of nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials, and photonics. In a recent interview, CEO Michael Weiner stated the benefits of performing surgical procedures under MRI are that you can see tissue better under MRI and neither the patient nor physician needs to be exposed to dangerous ionizing radiation.

Shares of BIPH closed at $2.65 on Monday on volume of 683,343 shares. Our recent alert adding BIPH to our watch list indicated that April 4, 2005, three months before Boston Scientific paid a premium to buy $5 million worth of Biophan's shares, Beacon Equity Research issued a report with a price target of $5.17. We believe Biophan has the potential to revolutionize the medical technology industry and investors looking for long term growth with near term results should consider buying the stock at these levels.

For more in-depth coverage of Biophan Technologies (BIPH) visit the Investor Relations section of their web site at http://www.biophan.com

Other stocks of interest this morning are: Swift Transportation reported earnings of $0.40 per share versus $0.43 last year on higher fuel costs.

International Business Machines reported second-quarter earnings of $1.12 versus an expected $1.03, after the close.

To recap financial markets Monday, U.S. stocks ended lower Monday, with the NASDAQ and the S&P 500 breaking a seven-session winning streak. Weaker-than-expected earnings from Citigroup Inc. prompted some investors to lock in recent gains. The Dow Jones Industrial Average dropped 65.84 points to 10,574.99, posting its first loss in four sessions. The NASDAQ Composite Index fell 11.91 points to 2,144.87 and the S&P 500 Index was down 6.79 points to 1,221.13, after ending last week at its highest level in four years. Volume was 1.2 billion on the Big Board, and 1.3 billion on the NASDAQ. Crude futures fell after OPEC cut their forecast for oil demand by 150,000 a barrels a day. Oil for August delivery eased 77 cents to $57.32 a barrel, its lowest level in over two weeks, but off an intraday low of $56.80. In currencies, the dollar weakened against the euro and the Japanese yen, ignoring positive U.S. capital-flows data for May. Gold futures extended a $3-an-ounce decline in the prior week. August gold closed 30 cents lower at $421. Long-term Treasury yields closed at a two-month highs; prices closed at their lows amid speculation Federal Reserve Chairman Alan Greenspan may send new signals this week that the Fed plans to keep raising rates. The benchmark 10-year note ended down 13/32 at 99 7/32 to yield 4.22%. Greenspan starts testimony to Congress on the state of the economy beginning Wednesday.

If you have a public company with an exciting story to tell, contact us at info@otcstockreview.com.

The email alert service provided by OTCStockReview.com is designed to notify investors of undervalued stocks, special situations, and long term growth opportunities. To subscribe to this free service, visit the OTC Stock Review home page at http://www.otcstockreview.com and select the Newsletter tab or send an email to newsletter@otcstockreview.com.

OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Furthermore, all information and/or opinions throughout this release are presented solely for informative purposes, and are not intended, nor should they be construed as investment advice. This release is a publication and service of OTC Stock Review, an independent research and investor-relations consulting firm that publishes investment-research reports and profiles on independently selected companies. Additionally, OTC Stock Review serves as a third party consultant to the Companies profiled and receives fees either in cash, stock or a combination thereof, for the services it provides, including reimbursed expenses for preparation and distribution of materials included in this release. In this regard, please see below for specific amounts of compensation that OTC Stock Review received in profiling a specific company. Officers, directors, and employees of OTC Stock Review, may hold a long or short equity position of a profiled Company and may from time to time trade in these securities for their own accounts. The information available on this release is not an offer to buy or sell securities of the Companies profiled on this release. Information disclosed in this release is subject to change without notice. Information pertaining to each Company profiled in this release was provided to OTC Stock Review, by the Company and cannot be guaranteed by OTC Stock Review. Companies profiled herein, including those companies listed on the website's "Watch List" or "News List" section, carry a high investment risk; readers should carefully review the profiled Companies thoroughly with their investment advisor, stockbroker, or other such professional. Additionally, the "Watch List" and "News List" profiled on the website is not a "buy list" in that there will be no buy or sell recommendations issued by OTC Stock Review on companies profiled in any form. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled Companies. Opinions stated are those of the indicated sources and not necessarily those of either OTC Stock Review or the Company being profiled in this release. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at http://www.sec.gov.

The purpose of this release is to introduce the reader to OTCStockReview.com and Biophan Technologies, Inc. This document contains public information about Biophan Technologies, Inc., but does not contain all the relevant material information necessary to evaluate the Company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of Biophan Technologies, Inc., as profiled. OTC Stock Review has been compensated $10,000.00 to perform investor relations services for Biophan Technologies, Inc. Principals of OTC Stock Review currently have a position in the shares of Biophan Technologies, Inc., purchased in the open market at an average cost of $2.56. You can view our complete disclaimer at http://www.otcstockreview.com/disclaimer.htm

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and OTCSR undertakes no obligation to update such statements.

Easily Send & Share Press Releases

GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.